Our study has revealed valuable information that GDF-15, CCL-20, CXCL-16, and CD8a biomarkers, which can be measured quantitatively by a simple and cost-effective ELISA method, can be a tool that can support molecular testing (PCR) in the clinical management of chronic hepatitis B patients. This evidence concerns the gene CCL20 and chronic hepatitis B virus infection.